Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study
Ritlecitinib alone and with nbUVB therapy improved facial and total body repigmentation and was well tolerated. Adding nbUVB may improve ritlecitinib efficacy.
Authors
- Pranab Ghosh (ORCID: https://orcid.org/0000-0002-2381-5435)
- Roni Adiri
- Emma Guttman‐Yassky (ORCID: https://orcid.org/0000-0002-9363-324X)
- Ronald N. Shore
- Elena Peeva
- Iltefat Hamzavi (ORCID: https://orcid.org/0000-0002-3137-5601)
- Khaled Ezzedine (ORCID: https://orcid.org/0000-0002-5468-4589)
- Amit G. Pandya (ORCID: https://orcid.org/0000-0002-3916-2651)
- Lynne Napatalung
- Yuji Yamaguchi (ORCID: https://orcid.org/0000-0003-4338-2662)
Institutions
- Pfizer (United States) (US)
- University of Maryland Eastern Shore (US)
- Henry Ford Hospital (US)
- Retina Foundation of the Southwest (US)
- 3M (Israel) (IL)
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1016/j.jaad.2024.11.064
- Citations
- 5
- Primary Topic
- melanin and skin pigmentation
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Celgene
- Regeneron Pharmaceuticals
- Dermira
- Glenmark Pharmaceuticals
- Galderma
- LEO Pharma